BridgeBio Pharma (FRA:2CL) Float Percentage Of Total Shares Outstanding: 89.58% (As of Jun. 30, 2026)


FRA:2CL BridgeBio Pharma Inc FRA:2CL
67 GF Score
Price €61.46
GF Value €122.60
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is BridgeBio Pharma Float Percentage Of Total Shares Outstanding?

BridgeBio Pharma FRA:2CL +2.55% 67 Float Percentage Of Total Shares Outstanding is 89.58% as of Jun. 30, 2026. GuruFocus rates FRA:2CL with a GF Score™ of 67/100 and a GF Value™ of €122.60 (Possible Value Trap). The stock has 8 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BridgeBio Pharma's float shares is 175.46 Mil. BridgeBio Pharma's total shares outstanding is 195.86 Mil. BridgeBio Pharma's float percentage of total shares outstanding is 89.58%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BridgeBio Pharma's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BridgeBio Pharma's Institutional Ownership is 36.82%.

FRA:2CL
67GF Score
BridgeBio Pharma Inc FRA:2CL
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

BridgeBio Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=175.46/195.86
=89.58%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 89.58% mean?
BridgeBio Pharma (FRA:2CL) has a Float Percentage Of Total Shares Outstanding of 89.58% as of Jun. 30, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on BridgeBio Pharma and its competitors.
Is BridgeBio Pharma's Float Percentage Of Total Shares Outstanding too high?
BridgeBio Pharma's current Float Percentage Of Total Shares Outstanding is 89.58%. Overall, BridgeBio Pharma has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Float Percentage Of Total Shares Outstanding compare to EXEL and IONS?
BridgeBio Pharma's Float Percentage Of Total Shares Outstanding of 89.58% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on BridgeBio Pharma and its competitors. BridgeBio Pharma's current Float Percentage Of Total Shares Outstanding is 89.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €122.60, compared to a current price of €61.46 — trading 49.9% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 89.58%. BridgeBio Pharma's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Float Percentage Of Total Shares Outstanding is 89.58% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €61.46 is trading 49.9% below its estimated GF Value™ of €122.60. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • Float Percentage Of Total Shares Outstanding: 89.58%
  • GF Value™: €122.60 vs. price of €61.46 (49.9% below fair value)
  • GF Score™: 67/100 with 8 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
67GF Score

Get the complete analysis for FRA:2CL

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€61.46
Price
€122.60
GF Value